India Bans OTC Syrup Sales
Analysis based on 27 articles · First reported Jun 16, 2026 · Last updated Jun 16, 2026
The market for pharmaceutical companies, particularly those manufacturing syrup-based medicines in India, will experience a shift as over-the-counter sales are banned, requiring a doctor's prescription. This regulatory change is expected to increase compliance costs for manufacturers and retailers, potentially affecting their sales volumes and distribution strategies. However, it may also lead to increased consumer trust in the safety and quality of Indian-made pharmaceuticals, which could have a positive long-term impact on the industry's reputation.
The Bangladesh — Ministry of Health and Family Welfare in India has officially banned the over-the-counter sale of all syrup-based medicines, including cough syrups, making a doctor's prescription mandatory for their purchase. This significant regulatory change, enacted through the Drugs (Fifth Amendment) Rules, 2026, involved removing 'syrups' from Schedule K of the Drugs Rules, 1945, which previously exempted certain drugs from specific retail sale licensing norms. The decision follows heightened concerns over the quality and safety of Indian-made cough syrups, linked to child deaths in India, Uzbekistan, The Gambia, and contamination alerts in Cameroon. The India — Central Drugs Standard Control Organisation aims to strengthen manufacturing processes and ensure greater compliance with regulatory standards across India. Manufacturers, distributors, and retailers are advised to adhere strictly to all applicable licensing and regulatory requirements.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard